FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease
Based on results of the DAPA-CKD trial, the FDA has granted approval for the diabetes drug in patients with CKD at risk for disease progression.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Nephrology News Alert Source Type: news
More News: Cardiology | Chronic Kidney Disease | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Urology & Nephrology